Commentary

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?

Yasunori Minami 1,*, Haruyuki Takaki 2, Koichiro Yamakado 2 and Masatoshi Kudo 1

1 Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi Osaka-Sayama, Osaka 589-8511, Japan; m-kudo@med.kindai.ac.jp
2 Department of Radiology, Hyogo College of Medicine, 1-1 Mukogawa Nishinomiya, Nishinomiya 663-8501, Japan; takakiharuyuki@gmail.com (H.T.); yamakado47@gmail.com (K.Y.)
* Correspondence: minskun@med.kindai.ac.jp; Tel.: +81-72-366-0221 (ext. 3525); Fax: +81-72-367-2880

Simple Summary: Although immune checkpoint inhibitors (ICIs) have achieved great progression in cancer treatment, the efficacy of ICI monotherapy is still limited. Meanwhile, the negative efficacy of thermal ablation for liver metastases is the high rate of local tumor progression. Since thermal ablation-induced inflammation and increases in tumor antigens have been suggested to promote the cancer-immunity cycle, thermal ablation and ICI can boost the immune response against cancer cells as one of the positive synergy effects. The findings of preclinical and clinical research have provided supportive evidence for the combination of ICIs with thermal ablation reversing T-cell exhaustion and demonstrating synergy. However, the clinical feasibility of immune response activation by combination therapy with ICI monotherapy and thermal ablation appears to be limited, it may be not very common phenomena.

Abstract: Cancer immunotherapy, which reactivates the weakened immune cells of cancer patients, has achieved great success, and several immune checkpoint inhibitors (ICIs) are now available in clinical practice. Despite promising clinical outcomes, favorable responses are only observed in a fraction of patients, and resistance mechanisms, including the absence of tumor antigens, have been reported. Thermal ablation involves the induction of irreversible damage to cancer cells by localized heat and may result in the release of tumor antigens. The combination of immunotherapy and thermal ablation is an emerging therapeutic option with enhanced efficacy. Since thermal ablation-induced inflammation and increases in tumor antigens have been suggested to promote the cancer-immunity cycle, the combination of immuno-oncology (IO) therapy and thermal ablation may be mutually beneficial. In preclinical and clinical studies, the combination of ICI and thermal ablation significantly inhibited tumor growth, and synergistic antitumor effects appeared to prolong the survival of patients with secondary liver cancer. However, evidence for the efficacy of ICI monotherapy combined with thermal ablation is currently insufficient. Therefore, the clinical feasibility of immune response activation by ICI monotherapy combined with thermal ablation may be limited, and thermal ablation may be more compatible with dual ICIs (the IO–IO combination) to induce strong immune responses.

Keywords: immune checkpoint inhibitor; immuno-oncology; information dissemination; liver metastasis; thermal ablation; tumor antigen

1. Introduction

Cancer immunotherapy has opened a new era in the field of oncology and may revolutionize cancer treatment for patients with advanced or metastatic solid tumors. Recent studies on immune checkpoint inhibitors (ICIs) demonstrated that their inhibitory effects prevented the blockade of the immune system by cancer cells attempting to escape their own destruction [1–3]. However, the efficacy of ICIs remains limited, and only a fraction of patients (<40%) respond to immuno-oncology (IO) drugs [4], which has been
attributed not only to the complexity of the immune system, but also to it being a tightly regulated network [5]. Several resistance mechanisms have been identified and include the absence of tumor antigens, T-cell exhaustion in the tumor microenvironment (TME), and overexpression of β-catenin [6]. Therefore, the enhancement of antitumor immune responses, as a strategy to overcome resistance to ICIs, is urgently needed.

Although hepatic resection remains the only potentially curative option for patients with secondary liver cancer, minimally invasive locoregional therapies, including radiofrequency and microwave ablation, have been used to treat unresectable liver metastases. The majority of thermal ablation systems consist of a generator and needle electrode that delivers energy directly to the targeted tumor for cell death. Thermal ablation may induce local inflammation and release multiple biomolecules, such as tumor antigens, into the circulation. Locoregional thermal ablation has the potential to promote anticancer immune responses [7–9], and a very rare event associated with this therapy is the abscopal effect, which induces spontaneous distant tumor regression [10]. However, immunomodulatory synergy by combination therapies may induce systemically effective antitumor immunity. The findings of preclinical and clinical studies revealed that the combination of ICIs and thermal ablation significantly inhibited tumor growth, and synergistic antitumor effects appeared to prolong the survival of patients with secondary liver cancer. We herein discuss the efficacy of immunotherapy combined with thermal ablation.

2. Background

2.1. Immune Resistance and Tumor Antigens

Cancer cells are either resistant to immunotherapy (primary resistance) or initially respond and then develop resistance (acquired resistance) [11]. Resistance may also be classified as intrinsic or extrinsic to tumor cells [12]. Tumor-intrinsic factors include the depletion of neoantigens, defective antigen presentation, aberrant interferon signaling, tumor-induced exclusion/immunosuppression, and plasticity of tumor cells. Tumor-extrinsic factors include the lack of tumor T-cell infiltration and immunosuppression in the TME. The combination of tumor-intrinsic and -extrinsic factors induces a resistance to therapy, which leads to three different outcomes: (i) an insufficient antitumor T-cell response, (ii) the inactivation of tumor-specific T cells, and (iii) a weak memory T-cell response [13].

There are various mechanisms of immune resistance. At the first step of the cancer immunity cycle, the lack of sufficient tumor antigens and alterations in antigen processing and/or tumor antigen presentation have been implicated in impaired antitumor T-cell responses [14,15], and inadequate T-cell functions may induce various immunosuppressive reactions in the TME [16]. As one of the positive synergy effects, tumor antigen release by thermal ablation and monoclonal antibodies, targeting either the programmed cell death protein (PD-1) or its ligand PD-L1, can boost the immune response against cancer cells (Figure 1).
were previously shown to be induced in tumor-draining lymph nodes, due to heat-induced which assisted in the maturation of dendritic cells and enhanced the tumor-specific cytotoxic T lymphocyte (CTL) response [23,24]. High levels of tumor-specific CD8+ T cells were previously shown to be induced in tumor-draining lymph nodes, due to heat-induced tumor damage [25,26]. Furthermore, antigen-presenting cells and tumor-infiltrating lymphocytes (TILs) were found to localize along the peripheral margin of the ablation zone [27]. Therefore, locoregional ablation therapy may provide a favorable TME for immune cells to function optimally, which will be beneficial when used in combination with ICIs [28,29].

3. Outcomes

3.1. Preclinical Studies

3.1.1. Ablation-Induced Immunomodulation

Shi et al. retrospectively investigated thermal ablation-induced immune responses in the tumor tissues of colorectal cancer patients with liver metastasis [8]. They enrolled 38 patients who underwent preoperative thermal ablation for liver metastasis, followed
by primary tumor resection (the ablation group), and 40 patients who underwent primary tumor resection alone (the non-ablation group). The number of TILs in the TME and degree of programmed death-ligand 1 (PD-L1) staining in tumor cells and lymphocytes were compared in colorectal cancer resection specimens. The median number of days between initial ablation for liver metastasis and surgical resection of the primary tumor was 6 (range, 4 to 10 days). Significantly higher levels of TILs were observed in the ablation group ($p < 0.001$), and the CD4/CD8 ratio was significantly higher in the ablation group ($p = 0.002$). These findings indicated that thermal ablation enhanced the tumor-specific immune responses and promoted the infiltration of CTLs into the TME.

3.1.2. Combination of Ablation and Immunotherapy in Mice

Shi et al. also compared the outcomes of CT26 tumor-bearing mice treated with RFA alone, PD-1 antibody alone, and the combination of thermal ablation and the anti-PD-1 antibody [8]. The injection of ICIs was repeated on days 1, 4, 7, and 10 after ablation. Recurrence was not detected in the ablation zone in any group. Although the modest inhibition of tumor growth was observed in the mice treated with ablation alone or the anti-PD-1 antibody alone, the inhibition of tumor growth and prolonged survival were observed in the group treated with the combination of ablation and the anti-PD-1 antibody. Furthermore, CD8+ T-cell depletion eliminated the inhibition of tumor growth in the combination therapy group, indicating the further enhancement of CD8+ T cell-mediated antitumor immunity by the combination of ablation and PD-1.

Zhu et al. investigated the outcomes of the following groups of 4T1 breast cancer cell-bearing mice: no treatment, the combination of PD-1 and cytotoxic T lymphocyte-associated antigen (CTLA)-4 blockers, thermal ablation alone, and thermal ablation in combination with ICIs [30]. The mice were injected 3 and 6 days after ablation. The combination of PD-1 and CTLA-4 blockers did not significantly affect mouse survival. Survival was significantly longer in the thermal ablation in combination with ICIs group than in the no treatment, ICIs alone, or thermal ablation alone group ($p < 0.001$, $p < 0.001$, and $p = 0.01$, respectively). In parallel experiments, tumor-bearing mice were sacrificed on day 10 after ablation. Serum IFN-γ levels were significantly higher in the thermal ablation in combination with ICIs group than in the no treatment, ICIs alone, or thermal ablation alone groups ($p < 0.001$, $p < 0.001$, and $p = 0.01$, respectively). The 4T1 ($n = 5$) or CT26 colon adenocarcinoma ($n = 5$) cells were then implanted on the opposite flanks of ten surviving mice in the thermal ablation in combination with ICIs group. On day 25, after the rechallenge, the outgrowth of reimplanted 4T1 cells was significantly delayed ($p = 0.002$); however, no significant delays were observed for reimplanted CT26 cells ($p = 0.905$). Collectively, these findings indicated that the induction of tumor-specific immune responses are not elicited from prior exposure to different cancers.

3.2. Clinical Studies

3.2.1. Oncological Outcomes

Since the initial approval of ipilimumab for the treatment of melanoma in 2011, several ICIs have been launched for cancer therapy. However, retrospective research on the combination of thermal ablation and ICIs has been limited.

McArthur et al. examined the tolerability of pre-operative cryoablation and/or ipilimumab in patients with operable breast cancer [31]. Patients were sequentially assigned into the following treatment groups: tumor cryoablation alone ($n = 7$), intravenous ipilimumab (10 mg/kg) alone ($n = 6$), and the combination of cryoablation and ipilimumab ($n = 6$). The cryoablation group was treated a median of 7 days before mastectomy (range, 4–10 days), and the ipilimumab group was treated a median of 10 days before mastectomy (range 8–13 days). The combination therapy group received ipilimumab a median of 3 days before undergoing cryoablation (range, 1–5 days). A peripheral blood flow cytometric analysis of the samples collected from the combination group revealed a sustained increase in the proportion of activated T cells, in both the CD4+ and CD8+ subsets. Furthermore, the
proportion of Ki67-positive CD4+ T cells and CD8+ T cells was higher in the combination therapy group than in either therapy group alone. However, neither the proportion of CD4+ T cells, CD8+ T cells, or regulatory T cells, nor the ratio of effector T cells to regulatory T cells, significantly differed among the treatment groups. The ratio of Ki67-positive effector T cells to regulatory T cells within the tumors was also higher in the combination group ($p = 0.05$). However, the expression levels of immune checkpoint markers, including CTLA-4, PD-1, and lymphocyte activation gene-3, on CD4 and CD8 TILs, at the time of tumor resection, were similar among the treatment groups. Collectively, these findings revealed sustained peripheral increases in Th1-type cytokine levels, activated and proliferating CD4+ and CD8+ T cell numbers, and post-treatment proliferative T-effector cell numbers, relative to the T-regulatory cell numbers within tumors by combination therapy.

Prospective clinical trials have investigated the efficacy of thermal ablation combined with immunomodulation for various types of malignant tumors. A non-randomized phase II study, evaluating the abscopal effect of pembrolizumab after radiotherapy or thermal ablation in patients with mismatch repair-proficient metastatic colorectal cancer, is ongoing (NCT02437071) [32].

3.2.2. Immune-Related Adverse Events (irAEs)

Leppelmann et al. retrospectively investigated whether interventional oncology procedures, performed in combination with anti–PD-1/PD-L1 therapy, increased the risk of irAEs in patients with different neoplasms [33]. Sixty-five patients (51% males; 63.1 ± 11.1 years) with melanoma ($n = 28$), non-small cell lung cancer ($n = 12$), hepatocellular carcinoma ($n = 3$), colorectal cancer ($n = 2$), and other malignancies were enrolled. They received anti-PD-1/PD-L1 agents ≤90 days before or ≤30 days after the interventional procedure, such as selective internal radiation therapy ($n = 28$), cryoablation ($n = 22$), thermal ablation ($n = 16$), and transarterial embolization ($n = 12$). The anti–PD-1/PD-L1 agents, pembrolizumab ($n = 30$), nivolumab ($n = 22$), and atezolizumab ($n = 6$), as well as the combination of ipilimumab and nivolumab ($n = 7$), were administered to patients. irAEs occurred in seven patients (10.8%), and the most common grade 1–2 complications were skin disorders ($n = 5$). Grade 3 irAEs, such as skin disorders ($n = 1$) and liver dysfunction ($n = 1$), were conservatively managed. The median time to the onset of irAEs was 33 days (interquartile range, 19–38 days). No unmanageable irAEs developed within 90 days of interventional treatments combined with ICIs.

3.2.3. Information Dissemination Considering Scientific Credibility

Patient decisions about appropriate health care for specific clinical should be based on the best available current, valid, and relevant evidence. The internet makes finding evidence for clinical practice easy. Much evidence about thermal ablation and cancer immunotherapy can be found; however, it is difficult to define that sufficient appropriate evidence has been accumulated. Then, the concept of the information dissemination model can be useful for evaluating the spread of medical information. Information dissemination analysis provides a more detailed understanding of complex social dynamics [34–37].

According to a simplified model analysis, an increase in the credibility of scientific information and its relevance to the daily lives of individuals will enhance the speed and final scale of information spreading (Figure 2A). Figure 2B shows PubMed-indexed medical publications, in terms of hepatitis C and interferon, as an example of information dissemination. Interferon was formerly the only antiviral drug for chronic hepatitis C infection. Although PubMed-indexed medical publications had increased, until recently, interferon-based treatment has been declining, since the introduction of interferon-free therapy with direct-acting antivirals in 2014. With the terms “lung cancer” and “immune checkpoint inhibitor”, PubMed-indexed medical publications have markedly increased, due to the development of promising IO treatments, whereas those with the terms “thermal ablation” and “immune checkpoint inhibitor” have not (Figure 2C).
Figure 2. Information dissemination. (A) Simple model of rumor spreading. The stronger the correlation degree between medical information and real-world evidence is, the larger the spreading scale of medical information and faster the speed of dissemination are. Red line: The curve of information dissemination when the credibility of scientific information was highest. Blue line: The curve of information dissemination when the credibility of scientific information was 2nd higher. Green line: The curve of information dissemination when the credibility of scientific information was tertiary. Light blue line: The curve of information dissemination when the credibility of scientific information was lowest. (B) Annual research reports indexed in PubMed for the terms “hepatitis C” and “interferon”. (C) Annual research reports indexed in PubMed: “lung cancer and immune checkpoint inhibitor” vs. “thermal ablation and immune checkpoint inhibitor”. Note, search terms 1*: lung cancer and immune checkpoint inhibitor; search terms 2†: thermal ablation and immune checkpoint inhibitor. Light grey: The number of publications per year with topics of lung cancer and immune checkpoint inhibitor. Dark grey: The number of publications per year with topics of thermal ablation and immune checkpoint inhibitor.
4. Summary

The efficacy of ICI monotherapy is still limited as a critical bottleneck, and an urgent medical question that needs to be addressed is how to convert an immune cold into a hot tumor. Meanwhile, the negative efficacy of thermal ablation for liver metastases is the high rate of local tumor progression [38,39]. There are each unmet needs for treatment efficacy. Here, we searched the manuscripts regarding synergistic effects in combination with IO and thermal ablation fairly. Among them, some preclinical/clinical manuscripts were selected, based on originality, logic, significance, and high impact on clinical application. Since thermal ablation-induced increases in tumor antigens have been suggested to promote the cancer-immunity cycle, the combination of IO therapy and thermal ablation may be mutually beneficial. The findings of preclinical and clinical research have provided supportive evidence for the combination of ICIs with thermal ablation reversing T-cell exhaustion and demonstrating clinical synergy; however, it cannot be very common phenomena. The speed of evidence accumulation on the combination of ICI monotherapy and thermal ablation has been insufficient. The clinical feasibility of immune response activation by combination therapy with ICI monotherapy and thermal ablation appears to be limited. Currently, combined immunotherapy is the treatment trend, and dual ICIs (IO–IO combination) are thought to prevent effector T-cell exhaustion, boosting the antitumor immune response powerfully. When synergistic effects in combination with ICI monotherapy are unacceptable, thermal ablation may be more compatible with dual ICIs (IO–IO combination) to induce strong immune responses.

Author Contributions: Literature acquisition/interpretation, Y.M. and H.T.; manuscript drafting and editing, Y.M.; manuscript revision for important intellectual content, H.T., K.Y. and M.K.; approval of the final version of the submitted manuscript, all authors. All authors have read and agreed to the published version of the manuscript.

Funding: No specific grant was obtained from any funding agency in the public, commercial, or not-for-profit sectors.

Conflicts of Interest: The authors declare no conflict of interest.

Ethics Approval: Ethics approval was not required for a review article.

Abbreviations

CEA carcinoembryonic antigen
CTL cytotoxic T lymphocyte
CTLA cytotoxic T lymphocyte-associated antigen
ICIs immune checkpoint inhibitors
IO immuno-oncology
irAEs immune-related adverse events
PD-1 programmed death-1
PD-L1 programmed death-ligand 1
TILs tumor-infiltrating lymphocytes
TME tumor microenvironment

References

1. Leach, D.R.; Krummel, M.F.; Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271, 1734–1736. [CrossRef] [PubMed]
2. Kwon, E.D.; Hurwitz, A.A.; Foster, B.A.; Madias, C.; Feldhaus, A.L.; Greenberg, N.M.; Burg, M.B.; Allison, J.P. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 1997, 94, 8099–8103. [CrossRef] [PubMed]
3. Ishida, Y.; Agata, Y.; Shibahara, K.; Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992, 11, 3887–3895. [CrossRef]
4. Kudo, M. Limited impact of anti-PD-1/PD-L1 monotherapy for hepatocellular carcinoma. Liver Cancer 2020, 9, 629–639. [CrossRef]
5. Hirsch, L.; Zitvogel, L.; Eggermont, A.; Marabelle, A. PD-Loma: A cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. Br. J. Cancer 2019, 120, 3–5. [CrossRef]
6. Dempke, W.C.M.; Fenchel, K.; Uciechowski, P.; Dale, S.P. Second- and third-generation drugs for immuno-oncology treatment-The more the better? *Eur. J. Cancer* 2017, 74, 55–72. [CrossRef] [PubMed]

7. Shen, S.; Peng, H.; Wang, Y.; Xu, M.; Lin, M.; Xie, X.; Peng, B.; Kuang, M. Screening for immune-potentiating antigens from hepatocellular carcinoma patients after radiofrequency ablation by serum proteomic analysis. *BMC Cancer* 2018, 18, 117. [CrossRef] [PubMed]

8. Shi, L.; Chen, L.; Wu, C.; Zhu, Y.; Xu, B.; Zheng, X.; Sun, M.; Wen, W.; Dai, X.; Yang, M.; et al. PD-1 blockade boosts radiofrequency ablation-elicted adaptive immune responses against tumor. *Clin. Cancer Res.* 2016, 22, 1173–1184. [CrossRef]

9. Minami, Y.; Nishida, N.; Kudo, M. Radiofrequency ablation of liver metastasis: Potential impact on immune checkpoint inhibitor therapy. *Eur. Radiol.* 2019, 29, 5045–5051. [CrossRef]

10. Takaki, H.; Cornelis, F.; Kako, Y.; Kobayashi, K.; Kamikonya, N.; Yamakado, K. Thermal ablation and immunomodulation: From preclinical experiments to clinical trials. *Diagn. Interv. Imaging* 2017, 98, 651–659. [CrossRef] [PubMed]

11. Sharma, P.; Hu-Lieskovan, S.; Wargo, J. A.; Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. *Cell* 2017, 168, 707–723. [CrossRef] [PubMed]

12. Fares, C.M.; Van Allen, E.M.; Drake, C.G.; Allison, J.P.; Hu-Lieskovan, S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? *Am. Soc. Clin. Oncol. Educ. Book* 2019, 39, 147–164. [CrossRef]

13. Mpakali, A.; Stratikos, E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. *Cancers* 2021, 13, 134. [CrossRef] [PubMed]

14. O’Donnell, J.S.; Long, G.V.; Scolyer, R.A.; Teng, M.W.L.; Smyth, M.J. Resistance to PD1/PDL1 checkpoint inhibition. *Cancer Treat. Rev.* 2017, 52, 71–81. [CrossRef]

15. Ton, N.; Schumacher, T.N.; Schreiber, R.D. Neoantigens in cancer immunotherapy. *Science* 2015, 348, 69–74.

16. Pitt, J.M.; Véziozou, M.; Daillère, R.; Roberti, M.P.; Yamazaki, T.; Routy, B.; Lepage, P.; Boneca, I.G.; Chamaillard, M.; Kroemer, G.; et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and Extrinsic Factors. *Immunity* 2016, 44, 1255–1269. [CrossRef]

17. Ahmed, M.; Brace, C.L.; Lee, F.T., Jr.; Goldberg, S.N. Principles of and advances in percutaneous ablation. *Radiology* 2011, 258, 351–369. [CrossRef]

18. Minami, Y.; Kudo, M. Radiofrequency ablation of liver metastases from colorectal cancer: A literature review. *Gut Liver* 2013, 7, 1–6. [CrossRef]

19. Vanagas, T.; Gulbinas, A.; Pundzius, J.; Barauskas, G. Radiofrequency ablation of liver tumors (I): Biological background. *Medicina* 2010, 46, 13–17. [CrossRef]

20. Leber, B.; Mayrhofer, U.; Leopold, B.; Koestenbauer, S.; Tscheleissnegg, K.; Stadlbauer, V.; Stiegler, P. Impact of temperature on cell death in a cell-culture model of hepatocellular carcinoma. *Anticancer Res.* 2012, 32, 915–921.

21. Ghanamah, M.; Berber, E.; Siperstein, A. Pattern of carcinoembryonic antigen drop after laparoscopic radiofrequency ablation of liver metastasis from colorectal carcinoma. *Cancer* 2006, 107, 149–153. [CrossRef] [PubMed]

22. Zhao, J.; Li, Q.; Muktiaili, M.; Ren, B.; Hu, Y.; Li, D.; Li, Z.; Xie, Y.; Tao, M.; et al. Effect of microwave ablation treatment of hepatic malignancies on serum cytokine levels. *BMC Cancer* 2020, 20, 812. [CrossRef]

23. van den Biggaart, R.J.E.; Schuurmans, F.; Fütterer, J.J.; Verheij, M.; Cornelissen, L.A.M.; Adema, G.J. Immune modulation plus tumor ablation: Adjuvants and antibodies to prime and boost anti-tumor immunity in situ. *Front. Immunol.* 2021, 12, 617365. [CrossRef] [PubMed]

24. den Brok, M.H.M.G.; Suttmuller, R.P.M.; Nierkens, S.; Bennink, E.J.; Frieling, C.A.; Toonen, L.W.J.; Boerman, O.C.; Figdor, C.G.; Ruers, T.J.M.; Adema, G.J. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. *Br. J. Cancer* 2006, 95, 896–905. [CrossRef] [PubMed]

25. Toraya-Brown, S.; Sheen, M.R.; Zhang, P.; Chen, L.; Baird, J.R.; Demidenko, E.; Turk, M.J.; Hoopes, P.J.; Conejo-Garcia, J.R.; Steven Fiering, S. Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. *Nanomedicine* 2014, 10, 1273–1285. [CrossRef] [PubMed]

26. Zhu, X.Q.; Lu, P.; Xu, Z.L.; Zhou, Q.; Zhang, J.; Wang, Z.B.; Wu, F. Alterations in Immune Response Profile of Tumor-Draining Lymph Nodes after High-Intensity Focused Ultrasound Ablation of Breast Cancer Patients. *Cells* 2021, 10, 3346. [CrossRef] [PubMed]

27. Rangamunwa, K.; Leong, T.; Weeden, C.; Asselin-Labat, M.L.; Bozinovski, S.; Christie, M.; John, T.; Antippa, P.; Irving, L.; Steinfort, D. Thermal ablation in non-small cell lung cancer: A review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. *Transl. Lung Cancer Res.* 2021, 10, 2842–2857. [CrossRef]

28. Mizukoshi, E.; Yamashita, T.; Arai, K.; Sunagokazaka, H.; Ueda, T.; Arihara, F.; Kagaya, T.; Yamashita, T.; Fushimi, K.; Kaneko, S. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. *Hepatolology* 2013, 57, 1448–1457. [CrossRef]

29. Heinrich, S.; Castven, D.; Galle, P.R.; Marquardt, J.U. Translational considerations to improve response and overcome therapy resistance in immunotherapy for hepatocellular carcinoma. *Cancers* 2020, 12, 2495. [CrossRef] [PubMed]

30. Zhu, J.; Yu, M.; Chen, L.; Kong, P.; Li, L.; Ma, G.; He, H.; Cui, Y.; Li, Z.; Pan, H.; et al. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model. *Diagn. Interv. Imaging* 2018, 99, 135–142. [CrossRef] [PubMed]

8 of 9
31. McArthur, H.L.; Diab, A.; Page, D.B.; Yuan, J.; Solomon, S.B.; Sacchini, V.; Comstock, C.; Durack, J.C.; Maybody, M.; Sung, J.; et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. *Clin. Cancer Res.* 2016, 22, 5729–5737. [CrossRef]

32. Segal, N.; Kemeny, N.; Cercek, A.; Reidy, D.; Rasch, P.; Warren, P.; Hrabovsky, A.E.; Campbell, N.; Shia, J.; Goodman, K.A.; et al. Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients. *J. Clin. Oncol.* 2016, 34, 3539. [CrossRef]

33. Leppelmann, K.S.; Mooradian, M.J.; Ganguli, S.; Uppot, R.N.; Yamada, K.; Irani, Z.; Wehrenberg-Klee, E.P.; Zubiri, L.; Reynolds, K.L.; Arellano, R.S.; et al. Thermal ablation, embolization, and selective internal radiation therapy combined with checkpoint inhibitor cancer immunotherapy: Safety analysis. *J. Vasc. Interv. Radiol.* 2021, 32, 187–195. [CrossRef] [PubMed]

34. Centora, D. The Spread of Behavior in an Online Social Network Experiment. *Science* 2010, 329, 1194–1197. [CrossRef] [PubMed]

35. Chen, X.; Wang, N. Rumor spreading model considering rumor credibility, correlation and crowd classification based on personality. *Sci. Rep.* 2020, 10, 5887. [CrossRef]

36. Wang, C.; Tan, Z.X.; Ye, Y.; Wang, L.; Cheong, K.H.; Xie, N.G. A rumor spreading model based on information entropy. *Sci. Rep.* 2017, 7, 9615. [CrossRef]

37. Salehinejad, S.; Jangipour Afshar, P.; Borhaninejad, V. Rumor surveillance methods in outbreaks: A systematic literature review. *Health Promot. Perspect.* 2021, 11, 12–19. [CrossRef]

38. Künzli, B.M.; Abitabile, P.; Maurer, C.A. Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future. *World J. Hepatol.* 2011, 3, 8–14. [CrossRef]

39. Petre, E.N.; Sofocleous, C. Thermal ablation in the management of colorectal cancer patients with oligometastatic liver disease. *Visc. Med.* 2017, 33, 62–68. [CrossRef] [PubMed]